

**TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED**  
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)  
(Company Registration No.: 91120000103100784F)  
(Incorporated in the People's Republic of China)

---

**RESOLUTIONS PASSED AT THE 4<sup>TH</sup> BOARD MEETING FOR FY2025**

---

***The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.***

On 20 June 2025, the Company duly convened its 4<sup>th</sup> Board meeting for the financial year ending 31 December 2025 (“**FY2025**”) via a combination of a physical meeting and teleconference. The said meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The full Board of nine (9) Directors were present, and the following resolutions were duly passed:

1. That the proposed entry into an equity custody agreement (股权托管协议) between the Company and Tianjin Medicine Asset Management Co., Ltd. (津药资产管理有限公司) and Tianjin Pharmaceutical Group Jin Yi Tang Chain Co., Ltd. (天津医药集团津一堂连锁股份有限公司) (the “**Target Company**”) in relation to custody of the 100% equity interest in the Target Company as an interested person transaction be approved.

Mr. Guo Min, Ms. Wang Lei, Mr. Xing Jianhua, and Ms. Mao Weiwen, being interested directors, abstained from voting on this resolution.

Please refer to the Company's announcement titled “*The Proposed Entry into an Equity Custody Agreement as an Interested Person Transaction*” released on the same date as this announcement for further information.

2. That the proposed entry into a lease agreement (房屋租赁合同) between the Company and Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) as an interested person transaction be approved.

Mr. Guo Min, Ms. Wang Lei, Mr. Xing Jianhua, and Ms. Mao Weiwen, being interested directors, abstained from voting on this resolution.

Please refer to the Company's announcement titled “*The Proposed Entry into a Lease Agreement as an Interested Person Transaction*” released on the same date as this announcement for further information.

3. That the proposed appointment of Ms. ZHAO Liyang (赵力扬) as the Company's securities affairs representative be approved.

**Ms. Zhao Liyang**, born in January 1990, is a Chinese national. She holds a Bachelor's degree in Management and a Master of Business Administration. From July 2013 to April 2016, she was

successively employed by Otis Elevator (China) Co., Ltd. (奥的斯电梯 (中国) 有限公司) and the Lerentang Pharmaceutical Factory of the Company. From May 2016 to May 2025, she served in Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) (“TPH”), successively holding roles as Officer and Supervisor in the Asset Management Department, and later as Assistant General Manager of TPH. Ms. Zhao joined the Company in June 2025.

**By Order of the Board**

Jiao Yan  
Secretary to the Board of Directors  
20 June 2025